[Podcast] Secure Innovation: How Life Sciences and Pharmaceutical Companies Can Safely Seize Opportunity

Published on October 25, 2023

The life sciences and pharmaceutical sector is constantly evolving and for companies to innovate and stay ahead of the curve, they need to be ready to capitalize on opportunities. Yet, success in life sciences hinges on safely seizing these chances amid inherent risks.

Join experts from NTT DATA as they discuss the complex challenges and solutions to maintaining safety and security in cybersecurity, quality assurance & regulatory compliance.

Check out the podcast episode below.

  1. Ep. 1 6 Steps to Strong Cybersecurity in Life Sciences Manufacturing

 

6 Steps to Strong Cybersecurity in Life Sciences Manufacturing

In the first episode of our three-part podcast series, “Secure Innovation: How Life Sciences Companies Can Safely Seize Opportunity,” hear from Phani Chaganti, head of Cyber Resilience at NTT DATA, on the 6-step roadmap to help life science companies assess and strengthen cybersecurity in life sciences. Learn about the major cybersecurity challenges in life sciences manufacturing, how to assess operational security and the difference between cybersecurity and compliance.

Continue reading on website
Other news

ESMO: AstraZeneca aims for ‘2.0’ cancer pipeline, shares bispecific data

October 25, 2023
AstraZeneca, home of cancer blockbusters like Tagrisso and Daiichi Sankyo-partnered Enhertu, wants to elevate its cancer pipeline and is sharing a peek at data from three bispecific antibody candidates at this year's European Society for Medical Oncology (ESMO) Congress.The Big Pharma’s “2.0 portfolio,” as Chief Medical Officer and Oncology Chief Development Officer Cristian Massacesi, M.D., calls

Ankyra Therapeutics Receives FDA IND and Health Canada CTA Approval to Advance First-In-Class Selective Anchored Immunotherapy Agent, ANK-101, into Human Trials in Solid Tumors

October 25, 2023
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Ankyra Therapeutics, a clinical stage biotechnology company pioneering anchored immunotherapies to treat cancer, today announced approval of its investigational new drug (IND) application by the U.S. Food & Drug Administration (FDA) and clinical trial application (CTA) by Health Canada for its lead agent, ANK-101, a novel tumor-directed anchored immune medicine.